Last reviewed · How we verify

Olmesartan/Amlodipin — Competitive Intelligence Brief

Olmesartan/Amlodipin (Olmesartan/Amlodipin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin II receptor blocker / Calcium channel blocker combination. Area: Cardiovascular.

phase 3 Angiotensin II receptor blocker / Calcium channel blocker combination AT1 receptor (angiotensin II type 1 receptor) / L-type calcium channel Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Olmesartan/Amlodipin (Olmesartan/Amlodipin) — Institut für Pharmakologie und Präventive Medizin. Olmesartan blocks angiotensin II receptors to lower blood pressure, while amlodipine blocks calcium channels to relax blood vessels and reduce cardiac workload.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Olmesartan/Amlodipin TARGET Olmesartan/Amlodipin Institut für Pharmakologie und Präventive Medizin phase 3 Angiotensin II receptor blocker / Calcium channel blocker combination AT1 receptor (angiotensin II type 1 receptor) / L-type calcium channel
Candemore Plus Tab Candemore Plus Tab Chong Kun Dang Pharmaceutical marketed Angiotensin II receptor blocker / Calcium channel blocker combination AT1 receptor; L-type calcium channel
valsartan/amlodipine valsartan/amlodipine Novartis marketed Angiotensin II receptor blocker / Calcium channel blocker combination AT1 receptor / L-type calcium channel
olmesartan medoxomil and a CCB olmesartan medoxomil and a CCB Daiichi Sankyo Co., Ltd. marketed Angiotensin II receptor blocker / Calcium channel blocker combination AT1 receptor; L-type voltage-gated calcium channel
Candesartan cilexetil/Amlodipine besylate Candesartan cilexetil/Amlodipine besylate HK inno.N Corporation marketed Angiotensin II receptor blocker / Calcium channel blocker combination AT1 receptor (angiotensin II type 1 receptor) / L-type voltage-gated calcium channel
valsartan/amlodpine valsartan/amlodpine University of Pavia marketed Angiotensin II receptor blocker / Calcium channel blocker combination AT1 receptor / L-type calcium channel
olmesartan medoxomil / amlodipine or azelnidipine olmesartan medoxomil / amlodipine or azelnidipine COLM Study Research Organization marketed Angiotensin II receptor blocker / Calcium channel blocker combination Angiotensin II type 1 receptor (AT1R); L-type voltage-gated calcium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiotensin II receptor blocker / Calcium channel blocker combination class)

  1. Handok Inc. · 3 drugs in this class
  2. Institut für Pharmakologie und Präventive Medizin · 2 drugs in this class
  3. Chong Kun Dang Pharmaceutical · 1 drug in this class
  4. Daiichi Sankyo Co., Ltd. · 1 drug in this class
  5. HK inno.N Corporation · 1 drug in this class
  6. Novartis · 1 drug in this class
  7. Boryung Pharmaceutical Co., Ltd · 1 drug in this class
  8. University of Pavia · 1 drug in this class
  9. COLM Study Research Organization · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Olmesartan/Amlodipin — Competitive Intelligence Brief. https://druglandscape.com/ci/olmesartan-amlodipin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: